Ethamsylate 250 mg Tranexamic Acid 250 mg Tablet

Ethamsylate

It exerts haemostatic action by acting on the first step of haemostasis by improving platelet adhesiveness and restoring capillary resistance. It decreases bleeding time and increases platelet aggregation. It reduces capillary bleeding when platelets are adequate. The drug exerts antihyaluronidase action and improves capillary wall stability. It inhibits PGI-2 synthesis and correct abnormal platelet function.

Tranexamic Acid

Tranexamic acid exerts antifibrinolytic effect by forming a reversible complex with plasminogen through the lysine binding site of fibrin and thus displaces the plasminogen from the fibrin surface ; preventing the binding of plasmin to fibrinogen or fibrin monomers. It inhibits the activation of plasminogen (i.e. formation of plasmin). It also acts as a weak non competitive inhibitor of plasmin and blocks it`s action on fibrin.

MK Medicine is a leading pcd franchise provider, contract manufacturer and hospital supplier of WHO-GMP certified Ethamsylate 250 mg Tranexamic Acid 250 mg Tablet